Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

Published on 9 Feb 2024 on Zacks via Yahoo Finance

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

The fourth-quarter earnings season entered its last lap this week, with Eli Lilly LLY and AstraZeneca AZN announcing their fourth-quarter and full-year 2023 results. Novo Nordisk NVO, Merck MRK and Novartis NVS made M&A announcements.

Recap of the Week’s Most Important Stories

Lilly & AstraZeneca Announce Q4 Earnings: Lilly’s fourth-quarter results were better than expected as it beat estimates for earnings as well as sales. The company witnessed strong sales growth of Mounjaro, Verzenio, Jardiance and Taltz, which made up for the decline in the sales of Trulicity in the quarter.

Read the rest of the article

NYSE.NVS price evolution

NASDAQ.MOR price evolution

SIX.NOVN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

NYSE.NVS price evolution

NASDAQ.MOR price evolution

SIX.NOVN price evolution

Want to become a better investor?

Novartis AG (NVS): Among the Best Global Stocks to Buy According to Hedge Funds

Is Novartis AG (NVS) the Best Foreign Dividend Stock to Buy According to...

Is Novartis AG (NVS) The Best Annual Dividend Stock To Buy Now?

Novartis AG's (VTX:NOVN) Stock On An Uptrend: Could Fundamentals Be Driving The...

Investing $50,000 in These 3 High-Yield Vanguard ETFs Can Generate Nearly $2,000...

Novartis to Report Q4 Earnings: What's in the Offing?

Here's what we'd like to see from our 8 stocks reporting earnings this week

Richemont’s Market Cap Surpasses CHF100 Billion

Trump’s Tariff Shifts Are a Warning for Corporate America to Expect Whiplash

Trump’s Tariff Shifts Are a Warning for Corporate America to Expect Whiplash